Prevention by aspirin and its combination with α-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon

Carcinogenesis

Volumn 20, Issue 3, 1999, Pages 425-430

  Li, Hong ^a   Schut, Herman A J ^a   Conran, Philip ^a   Kramer, Paula M ^a   Lubet, Ronald A ^b   Steele, Vernon E ^b   Hawk, Ernest E ^b   Kelloff, Gary J ^b   Pereira, Michael A ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZOXYMETHANE; EFLORNITHINE; HALOAMINO ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ARTICLE; CANCER PREVENTION; COLON CANCER; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032993593     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.3.425     Document Type: Article

References (50)

1. World Health Organization (1997) The World Health Report. WHO, Geneva, Switzerland.
2. Marnett, L.J. (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52, 5575-5589.
3. Thun, M.J., Namboodiri, M.M. and Heath, C.W. (1975) Aspirin use and reduced risk of fatal colon cancer. New Engl. J. Med., 325, 1593-1596.
4. Thun, J.M., Namboodiri, M.M., Calle, E.E., Flanders, W.D. and Heath, C.W. (1993) Aspirin use and risk of fatal cancer. Cancer Res., 53, 1322-1327.
5. Rosenberg, L., Palmer, J.R., Zauber, A.G., Warshaner, M.E., Stolley, P.D. and Shapire, S. (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of the large-bowel cancer. J. Natl Cancer Inst., 83, 355-358.
6. Martinez, M.E., Mcpherson, R.S., Levin, B. and Annegers, J.F. (1995) Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol. Biomarkers Prev., 4, 703-707.
7. Paganini-Hill, A., Hsu, G., Ross, R.K. and Henderson, B.E. (1991) Aspirin use and incidence of large-bowel cancer in a California retirement community. J. Natl Cancer Inst., 83, 1182-1183.
8. Reddy, B.S., Rao, C.V., Rivenson, A. and Kelloff, G. (1993) Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis, 14, 1493-1497.
9. Wargovich, M.J., Chen, C.D., Harris, C., Yang, E. and Velasco, M. (1995) Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int. J. Cancer, 60, 515-519.
10. Pereira, M.A., Barnes, L.H., Rassman, V.L., Kelloff, G.V. and Steele, V.E. (1994) Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis, 15, 1049-1054.
11. Craven, P.A. and DeRubertis, F.R. (1992) Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis, 13, 541-546.
12. Pence, B.C., Dunn, D.M., Zhao, C., Landers, M. and Wargovich, M.J. (1995) Chemopreventive effects of calcium but not aspirin supplementation in cholic acid-promoted colon carcinogenesis: correlation with intermediate endpoints. Carcinogenesis, 16, 757-765.
13. Reddy, B.S., Maruyama, H. and Kelloff, G. (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a non-steroidal anti-inflammatory drug during different stages of rat colon tumor development. Cancer Res., 47, 5340-5346.
14. Pereira, M.A., Barnes, L.H., Steele, V.E., Kelloff, G.V. and Lubet, R.A. (1996) Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis, 17, 373-376.
15. Rao, C.V., Rivenson, A., Simi, B., Zang, E., Kelloff, G.V., Steele, V.E. and Reddy, B.S. (1995) Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55, 1464-1472.
16. Reddy, B.S., Nayini, J., Tokumo, K., Rigotty, J., Zang, E. and Kelloff, G.V. (1990) Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D.L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor in diet. Cancer Res., 50, 2562-2568.
17. Rao, C.V., Tokumo, K., Rigotty, J., Zang, E., Kelloff, G.V. and Reddy, B.S. (1991) Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16α-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res., 51, 4528-4534.
18. Lands, W.E.M. and Hanel, A.,M. (1983) Inhibitors and activators of prostaglandins biosynthesis. In Pace-Asciak, C. and Granstorm, E. (eds) Prostaglandins and Related Substances. North Holland Biomedical Press, Amsterdam, Elsevier, pp. 203-223.
19. Roth, G.J. and Majerus, P.W. (1975) The mechanism of the effect of aspirin on human platelets 1. Acetylation of a particulate fraction protein. J. Clin. Invest., 56, 624-632.
20. Bennett, A. and del Tacca, M. (1975) Prostaglandins in human colonic carcinoma. Gut, 16, 409.
21. Jaffe, B.M. (1974) Prostaglandins and cancer: an update. Prostaglandins, 6, 453-461.
22. Karmali, R. (1985) Lipid nutrition, prostaglandins and cancer. In Lands, W.E.M. (ed.) Biochemistry of Arachidonic Acid Metabolism. Martinus Nijhoff Press, Boston, MA, pp. 203-211.
23. 2 and liver and lung metastases in colorectal cancer. Dis. Colon Rectum, 33, 840-845.
24. Pegg, A.E. (1988) Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res., 48, 759-774.
25. Pegg, A.E. (1986) Recent advances in the biochemistry of polyamines in eukaryotes. Biochem. J., 234, 249-262.
26. McCann, P.P., Bitoni, A.J. and Pegg, A.E. (1992) Inhibition of polyamine metabolism and the consequent effects on cell proliferation., In Wattenberg, L., Lipkin, M., Boone, C.W. and Kelloff, G.J. (eds) Cancer Chemoprevention. CRC Press, Boca Raton, FL, pp. 531-539.
27. Verma, A.K. (1989) The enzyme-activated irreversible inhibitor of ornithine decarboxylase, D.L-α-difluoromethylornithine: a chemopreventive agent. Prev. Med., 18, 646-652.
28. Nigro, N.D., Bull, A.W., Wilson, P.S., Soullier, B.K. and Alousi, M.A. (1982) Combined inhibitions of carcinogenesis: effect on azoxymethane-induced intestinal cancer in rats. J. Natl Cancer Inst., 69, 103-107.
29. Luk, G.D., Hamilton, S.R., Yong, P. Smith, J.A., O'Ceallaigh, D., McAvinchey, D. and Hyland, J. (1986) Kinetic changes in mucosal ornithine decarboxylase activity during azoxymethane-induced colonic carcinogenesis in the rat. Cancer Res., 46, 4449-4452.
30. Luk, G.D., Zang, S.Z. and Hamilton, S.R. (1989) Effects of timing of administration and dose of difluoromethylornithine on rat colonic carcinogenesis. J. Natl Cancer Inst., 81, 421-427.
31. Sing, J, Kelloff, G. and Reddy, B.S. (1992) Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis. Cancer Epidemiol. Biomarkers Prev., 1, 405-411.
32. Kullkarni, N., Zang, E., Kelloff, G.J. and Reddy, B.S. (1992) Effect of the chemopreventive agents piroxicam and D.L-α-difluoromethylornithine on intermediate biomarkers of colon carcinogenesis. Carcinogenesis, 13, 995-1000.
33. Pereira, M.A. and Khoury, M.D. (1991) Prevention by chemopreventive agents of azoxymethane-induced foci of aberrant crypts in rat colon. Cancer Lett., 61, 27-33.
34. Bird, R.P. (1987) Observations and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett., 37, 147-151.
35. Wyllie, A.H., Kerr, J.F.R. and Currie, A.R. (1980) Cell death: the significance of apoptosis. Int. Rev. Cytol., 68, 251-306.
36. Steel, V.E., Moon, R.C., Lubet, R.A. et al. (1994) Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI chemoprevention drug development program. J. Cell. Biochem., 20, 32-54.
37. Cohen, S.M., Zenser, T.V., Murasaki, G., Fukushima, S., Mattammal, M.B., Rapp, N.S. and Davis, B.B. (1981) Aspirin inhibition of N-[4-(5-nitro-2-furyl)-2-thiazoly]formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase. Cancer Res., 41, 3355-3359.
38. Sakata, T., Hasegawa, R., Johansson, S.J., Zenser, T.V. and Cohen, S.M. (1986) Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazoly]formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. Cancer Res., 46, 3903-3906.
39. Sharma, S., Zhu, S., Jokinen, M.P., Steele, V.E. and Kelloff, G.J. (1995) Dysplasia and gamma glutamyl transpeptidase as intermediate endpoint markers for N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in rats and the chemopreventive effect of aspirin. Proc. Am. Assoc. Cancer Res., 35, A3735.
40. Shiff, S.J., Qiao, L., Tsai, L.L. and Rigas, B (1995) Sulindac sulfide, an aspirin-like compound, inhibits proliferation, cause cell cycle quiescence and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest., 96, 491-503.
41. Elder, D.J., Hague, A., Hicks, D.J. and Paraskeva, C. (1996) Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res., 56, 2273-2276.
42. Hison, L., Albert, D., Krutzsch, M. et al. (1994) Antiproliferative effect of nonsteroidal anti-inflammatory drugs (NSAIDs) against human colon cancer cells. Cancer Epidemiol. Biomarkers Prev., 3, 433-438.
43. Piazza, G.A., Kulchak-Rahm, A.L., Krutzsch, M. et al. (1995) Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55, 3110-3116.
44. Goldberg, Y., Pittas, K. and Reed, J.C. (1995) Sulindac and sulindac sulfide alter the levels of bcl-2 and bax proteins in HT-29 colon cancer cells. Gastroenterology, 108A, 475-481.
45. Bedi, A., Pasricha, P.J., Barber, J.P., Bedi, G.C., Piantadosi, S., Giardiello, F.M., Zehnbauer, B.A., Hamilton, S.R. and Jones, R.J. (1995) Inhibition of apoptosis during development of colorectal cancer. Cancer Res., 55, 1811-1816.
46. Pasricha, P.J., Bedi, A., O'Connor, K., Rashid, A., Akhar, A.J., Zahurak, M.L., Piantadosi, S., Hamilton, S.R. and Giardiello, F.M. (1995) The effects of sulindac on colorectal proliferation and apoptosis in familial adenomalous polyposis. Gastroenterology, 109, 994-998.
47. Boolbol, S.K., Dannenberg, A.J., Chadburn, A. et al. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56, 2556-2560.
48. Samaha, H.S., Kelloff, G.J., Steele, V.E., Rao, C.V. and Reddy, B.S. (1995) Modulation of apotosis by sunlindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res., 57, 1301-1305.
49. Zheng, Y., Kramer, P.M., Lubet, R.A., Steele, V.E., Kelloff, G.J. and Pereira, M.A. (1999) Effect of retinoids on AOM-induced colon cancer in rats: Modulation of cell proliferation, apoptosis and aberrant crypt foci. Carcinogenesis, 20, 255-260.
50. Zheng, Y., Kramer, P.M., Olson, G., Lubet, R.A., Steele, V.E., Kellof, G.J. and Pereira, M.A. (1997) Prevention by retinoids of azoxymethane-induced colon cancer and aberrant crypt foci and their modulation of cell proliferation in rats. Carcinogenesis, 18, 2119-2125.